Synendos Therapeuthics

Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos’ newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders.

Press releases

12. November 2020

Synendos Therapeutics Raises CHF 20 Million in Series A Financing

Breakthrough approach to developing safe and effective therapies for unmet needs in neuropsychiatric disorders Financing will allow Synendos Therapeutics to complete pre-clinical development and progress lead candidate through proof of concept clinical study Supported by strong European investor syndicate co-led by Kurma Partners and Sunstone Life Science Ventures Synendos Therapeutics (Synendos), a biopharmaceutical company developing a new class of small molecules aimed at restoring the

Info & Contact


Gewerbestrasse, 24
4123 - Allschwil (Switzerland)

In portfolio

31. Oct 2020


HTGF Manager

Dr. Laura Pedroza, Investment Manager